The benzene hematotoxic and reactive metabolite 1,4-benzoquinone impairs the activity of the histone methyltransferase SETD2 and causes aberrant H3K36 trimethylation (H3K36me3)
暂无分享,去创建一个
V. Sirri | C. Chomienne | N. Dulphy | J. Dupret | F. Guidez | L. Bui | J. Berthelet | F. Rodrigues-Lima | C. Michail | Louise Le Coadou | Li | Wang
[1] C. Chomienne,et al. Human CREBBP acetyltransferase is impaired by etoposide quinone, an oxidative and leukemogenic metabolite of the anticancer drug etoposide through modification of redox-sensitive zinc-finger cysteine residues. , 2020, Free radical biology & medicine.
[2] C. North,et al. Modes of Action Considerations in Threshold Expectations for Health Effects of Benzene. , 2020, Toxicology letters.
[3] J. Workman,et al. Regulation of SETD2 stability is important for the fidelity of H3K36me3 deposition , 2020, Epigenetics & chromatin.
[4] L. Winn,et al. Benzene and its effects on cell signaling pathways related to hematopoiesis and leukemia , 2020, Journal of applied toxicology : JAT.
[5] Z. Herceg,et al. The Promises and Challenges of Toxico-Epigenomics: Environmental Chemicals and Their Impacts on the Epigenome , 2020, Environmental health perspectives.
[6] P. Hägglund,et al. Modification of Cys residues in human thioredoxin-1 by p-benzoquinone causes inhibition of its catalytic activity and activation of the ASK1/p38-MAPK signalling pathway , 2019, Redox biology.
[7] O. Gozani,et al. Histone lysine methyltransferases in biology and disease , 2019, Nature Structural & Molecular Biology.
[8] L. Winn,et al. DNA Damage and Perturbed Topoisomerase IIα as a Target of 1,4-Benzoquinone Toxicity in Murine Fetal Liver Cells. , 2019, Toxicological sciences : an official journal of the Society of Toxicology.
[9] Elias S. J. Arnér,et al. Inhibition and crosslinking of the selenoprotein thioredoxin reductase-1 by p-benzoquinone , 2019, Redox biology.
[10] Ximing Xu,et al. Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling , 2019, The Journal of Biological Chemistry.
[11] Y. Hayashi,et al. SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints , 2019, Leukemia.
[12] M. Davies,et al. Kinetics and biological consequences of quinone-induced protein adduction , 2018, Free Radical Biology & Medicine.
[13] Weiguo Zou,et al. H3K36 trimethylation mediated by SETD2 regulates the fate of bone marrow mesenchymal stem cells , 2018, PLoS biology.
[14] Z. Yi,et al. Benzene metabolite 1,2,4-benzenetriol changes DNA methylation and histone acetylation of erythroid-specific genes in K562 cells , 2018, Archives of Toxicology.
[15] U. Matte,et al. The role of B7 costimulation in benzene immunotoxicity and its potential association with cancer risk , 2018, Environmental research.
[16] A. Krężel,et al. Metal binding properties, stability and reactivity of zinc fingers , 2018, Coordination Chemistry Reviews.
[17] Y. Hayashi,et al. Setd2 regulates quiescence and differentiation of adult hematopoietic stem cells by restricting RNA polymerase II elongation , 2018, Haematologica.
[18] Saijuan Chen,et al. Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation , 2018, Cell Research.
[19] J. Mecinović,et al. Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II). , 2018, Bioorganic & medicinal chemistry letters.
[20] S. Armstrong,et al. SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. , 2017, Blood.
[21] I. Davis,et al. SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation. , 2017, Cold Spring Harbor Perspectives in Medicine.
[22] S. Jia,et al. Molecular basis for the role of oncogenic histone mutations in modulating H3K36 methylation , 2017, Scientific Reports.
[23] J. Bolton,et al. Formation and Biological Targets of Quinones: Cytotoxic versus Cytoprotective Effects , 2016, Chemical research in toxicology.
[24] Andy H. Vo,et al. Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation* , 2016, The Journal of Biological Chemistry.
[25] C. Allis,et al. Molecular basis for oncohistone H3 recognition by SETD2 methyltransferase , 2016, Genes & development.
[26] Gerben Duns,et al. SETD2: an epigenetic modifier with tumor suppressor functionality , 2016, Oncotarget.
[27] Ivan Rusyn,et al. Epigenetic alterations induced by genotoxic occupational and environmental human chemical carcinogens: A systematic literature review. , 2016, Mutation research. Reviews in mutation research.
[28] S. Gangemi,et al. Benzene exposure is associated with epigenetic changes (Review). , 2016, Molecular medicine reports.
[29] S. Bohlander,et al. Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases. , 2015, Cancer genetics.
[30] Kristina M. Cook,et al. Inhibition of the HIF1α-p300 interaction by quinone- and indandione-mediated ejection of structural Zn(II). , 2015, European journal of medicinal chemistry.
[31] A. Jeltsch,et al. Role of somatic cancer mutations in human protein lysine methyltransferases. , 2014, Biochimica et biophysica acta.
[32] B. Sonawane,et al. Lymphohematopoietic cancers induced by chemicals and other agents and their implications for risk evaluation: An overview. , 2014, Mutation research. Reviews in mutation research.
[33] Heather L. Mulder,et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes , 2014, Nature Communications.
[34] S. Armstrong,et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in pediatric acute lymphoblastic leukemia , 2014, Nature Communications.
[35] S. Mi,et al. Identification of functional cooperative mutations of SETD2 in human acute leukemia , 2014, Nature Genetics.
[36] C. Lim,et al. Identification of labile Zn sites in drug-target proteins. , 2013, Journal of the American Chemical Society.
[37] Sharon Y. R. Dent,et al. The role of chromatin modifiers in normal and malignant hematopoiesis. , 2013, Blood.
[38] R. H. Simoyi,et al. Substituent effects on the reactivity of benzoquinone derivatives with thiols. , 2013, Chemical research in toxicology.
[39] Luoping Zhang,et al. Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment. , 2012, Carcinogenesis.
[40] E. Wagner,et al. Understanding the language of Lys36 methylation at histone H3 , 2012, Nature Reviews Molecular Cell Biology.
[41] C. Skibola,et al. Benzene, the exposome and future investigations of leukemia etiology. , 2011, Chemico-biological interactions.
[42] S. Quintal,et al. Zinc finger proteins as templates for metal ion exchange and ligand reactivity. Chemical and biological consequences. , 2011, Metallomics : integrated biometal science.
[43] N. Rothman,et al. Human benzene metabolism following occupational and environmental exposures. , 2010, Chemico-biological interactions.
[44] Martyn T. Smith,et al. Advances in understanding benzene health effects and susceptibility. , 2010, Annual review of public health.
[45] L. Mahadevan,et al. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation , 2007, The EMBO journal.
[46] N. Osheroff,et al. Quinone-induced enhancement of DNA cleavage by human topoisomerase IIalpha: adduction of cysteine residues 392 and 405. , 2007, Biochemistry.
[47] Brent A. Johnson,et al. Modeling Human Metabolism of Benzene Following Occupational and Environmental Exposures , 2006, Cancer Epidemiology Biomarkers & Prevention.
[48] Brent A. Johnson,et al. Using urinary biomarkers to elucidate dose-related patterns of human benzene metabolism. , 2006, Carcinogenesis.
[49] P. Hatcher,et al. Mechanism of arylating quinone toxicity involving Michael adduct formation and induction of endoplasmic reticulum stress. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[50] D. Eastmond,et al. Topoisomerase II inhibition by myeloperoxidase-activated hydroquinone: a potential mechanism underlying the genotoxic and carcinogenic effects of benzene. , 2005, Chemico-biological interactions.
[51] Robert A Copeland,et al. Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. , 2005, Methods of biochemical analysis.
[52] N. Osheroff,et al. 1,4-Benzoquinone is a topoisomerase II poison. , 2004, Biochemistry.
[53] M Vijayaraj Reddy,et al. Genotoxicity of benzene and its metabolites. , 2004, Mutation research.
[54] D. Eastmond,et al. Inhibition of human topoisomerase II in vitro by bioactive benzene metabolites. , 1996, Environmental health perspectives.
[55] P Grasso,et al. Leukemia and benzene. , 1983, Annals of internal medicine.